Current joint therapy usage in equine practice: a survey of veterinarians 2009.
Authors: Ferris D J, Frisbie D D, McIlwraith C W, Kawcak C E
Journal: Equine veterinary journal
Summary
# Editorial Summary: Joint Therapy Usage in Equine Practice A 2011 survey of 831 American veterinarians revealed striking patterns in how intra-articular medications are prescribed across different equine disciplines, with corticosteroid choice largely dependent on joint classification and clinical focus. Triamcinolone acetonide dominated high-motion joint treatment (77% of respondents), whilst methylprednisolone acetate was preferred for low-motion joints (73%), though racehorse practitioners showed significantly lower uptake of triamcinolone, suggesting discipline-specific protocols influence decision-making. Disease-modifying agents saw more consistent usage, with polysulphated glycosaminoglycan (63%) and hyaluronate sodium (57%) commanding the majority, whilst regenerative biologics like IRAP were notably favoured by sport horse veterinarians over racing or showing practitioners. Perhaps most notably, experience level mattered substantially—vets in practice for over a decade were significantly less likely to include antimicrobials in joint injections compared to their newer colleagues, implying evolving best practices around infection risk assessment. These findings suggest that pharmaceutical choices in equine joint therapy remain inconsistent across practice types and clinician experience, highlighting both an opportunity for evidence-based standardisation and important baseline data for targeting future clinical research towards the most controversial or variable treatment decisions.
Read the full abstract on PubMed
Practical Takeaways
- •Current practice shows clear preference for TA in high motion joints and MPA in low motion joints; consider aligning protocols with peer practice patterns while evaluating individual case outcomes
- •Disease-modifying agents (Adequan and Legend) are standard of care in the majority of practices, suggesting consideration for routine use alongside corticosteroids
- •Joint injection protocols vary significantly by discipline and experience level; reassess antimicrobial use in joint injections as recent evidence and mentorship from experienced practitioners may inform safer, more effective protocols
Key Findings
- •77% of equine veterinarians use triamcinolone acetonide (TA) for high motion joints versus 73% using methylprednisolone acetate (MPA) for low motion joints
- •Polysulfated glycosaminoglycan (Adequan) and hyaluronate sodium (Legend) were the most commonly used disease-modifying products at 63% and 57% respectively
- •Significant variation exists in joint medication usage based on primary discipline (Western/Sport horses versus racehorses) and years in practice
- •Veterinarians in practice >10 years were significantly less likely to use antimicrobials in joint injections compared to those in practice <10 years